Layoffs have hit biopharma hard over the last year and a half. In this episode Fierce's Max Bayer and Gabrielle Mason will discuss the recent trends. We'll also cover a gene therapy by Sarepta Therapeutics, Abbott's FDA approval, plus this week's headlines. 

To learn more about the topics in this episode: 

• Layoffs continue to batter biotech, with Big Pharmas piling on the pain
• Abbott's spinal cord stimulators score FDA approval to treat nonsurgical back pain
• Theranos' Elizabeth Holmes ordered to report to prison amid appeal, fined $452M in restitution alongside Sunny Balwani
• UPDATED: FTC sues to block Amgen's $28B Horizon buy in alarming sign for biopharma M&A
• UPDATED: FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy

"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.